<DOC>
	<DOCNO>NCT00088283</DOCNO>
	<brief_summary>Eyetech Pharmaceuticals Inc. Pfizer , Inc. study investigational drug , MacugenTM , possible treatment CRVO . An investigational drug one approve U.S. Food Drug Administration ( FDA ) . This investigational drug may slow growth abnormal blood vessel eye may reduce tissue swell eye . The purpose study compare safety efficacy Macugen™ injection “ pretend ” injection . In addition , purpose study measure action study drug body period time check presence study drug blood ( call pharmacokinetics PK ) . This study involve approximately 90 people . People decide participate equal chance ( 1 3 ) receive one three study injection , two Macugen™ one “ pretend ” injection .</brief_summary>
	<brief_title>Pegaptanib Sodium Compared Sham Injection Patients With Recent Vision Loss Due Macular Edema Secondary Central Retinal Vein Occlusion ( CRVO )</brief_title>
	<detailed_description>This study consist 3 phase : screening phase last two week , confirmation phase last one day , randomization phase ( patient assign chance study group phase ) last approximately 52 week .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>CRVO must occur within past 6 month associate macular edema determine OCT . Vision study eye correspond approximately 20/50 20/400 good equal approximately 20/200 fellow eye . Presence sign old branch retinal vein occlusion ( BRVO ) CRVO study eye retinal vascular disease include diabetic retinopathy . Vitreous hemorrhage except breakthrough hemorrhage intraretinal hemorrhage . Prior pan retinal photocoagulation ( PRP ) sector scatter photocoagulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>CRVO</keyword>
	<keyword>Central Retinal Vein Occlusion</keyword>
	<keyword>RVO</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
</DOC>